Treatment with evolocumab significantly reduced low-density lipoprotein cholesterol but had no notable impact on glycemic measures in Chinese patients with type 2 diabetes and dyslipidemia.
Compared with men, women in whom diabetes develops experience greater changes in the cumulative burden of cardiovascular risk factors from young to middle-age adulthood, which may contribute to a higher risk for CVD events.
Investigators evaluated whether treatment with one year of oral or transdermal administration of estrogen plus cyproterone and transdermal or intramuscular application of testosterone caused changes in serum lipids and blood pressure.
Children with normal timing of BMI peak who experienced an early adiposity rebound or without any BMI decline after infancy appear to have the highest risk of developing an adverse cardiometabolic profile in adolescence.
Treatment with sitagliptin had no effect on soluble CD14 when given to participants with virally suppressed HIV infection.
Increased glucose levels in middle-aged adults that include the development of diabetes are associated with a higher risk for cardiovascular disease.
Despite research suggesting that there may be increased cardiovascular risk from off-label prescription testosterone use, usage in men with coronary artery disease remains higher than in men without coronary artery disease.
Intensive multifactorial interventions that are implemented in a multi-ethnic population with type 2 diabetes led to sustained improvements in a model of cardiovascular disease outcomes.
Treatment with levothyroxine in patients with heart failure is associated with a higher risk for all-cause mortality, cardiovascular death, and major adverse cardiac events.
SYNTAX score, a validated prediction score used to estimate risk with PCI, is modestly correlated with hard cardiovascular events and is significantly correlated with major adverse cardiac and cerebrovascular events
